The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022

December 5, 2025 updated by: asmaa salama ibrahim, Suez Canal University
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors. The most common sites of GI carcinoids are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). Some studies reported an association between neuroendocrine tumors and multiple malignancies. However, the presence of neuroendocrine tumors combined with multiple primary GI tumors is considered an exotic event in the literature with only few case studies and case series. So the aim of this study is to assess the risk of GI malignancies following primary GI carcinoids.

Study Overview

Status

Completed

Conditions

Detailed Description

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors. The most common sites of GI carcinoids are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). Some studies reported an association between neuroendocrine tumors and multiple malignancies. However, the presence of neuroendocrine tumors combined with multiple primary GI tumors is considered an exotic event in the literature with only few case studies and case series. So the aim of this study is to assess the risk of GI malignancies following primary GI carcinoids.

Study Type

Observational

Enrollment (Actual)

93481

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients diagnosed with gastrointestinal carcinoid tumor

Description

Inclusion Criteria:

  • patients diagnosed with gastrointestinal carcinoid tumor.
  • patients diagnosed from 2000 till 2022

Exclusion Criteria:

  • patients diagnosed with autopsy only or death certificate only.
  • patients lacking age documentation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The standardized incidence ratio and excess risk of second primary gastrointestinal malignancies following primary gastrointestinal carcinoid tumors
Time Frame: Jan, 2000 till Dec, 2022
The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess risk for second primary gastrointestinal malignancies following primary gastrointestinal carcinoid tumors
Jan, 2000 till Dec, 2022
The standardized incidence ratio and excess risk of gastrointestinal second primary malignancies stratified according to the primary gastrointestinal carcinoids site.
Time Frame: from Jan, 2000 till Dec, 2022
from Jan, 2000 till Dec, 2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Suez Canal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2000

Primary Completion (Actual)

December 30, 2022

Study Completion (Actual)

December 30, 2022

Study Registration Dates

First Submitted

December 5, 2025

First Submitted That Met QC Criteria

December 5, 2025

First Posted (Actual)

December 18, 2025

Study Record Updates

Last Update Posted (Actual)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 5, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A276

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoid Tumor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe